

**Advances in Diagnosis**  
**and**  
**Treatment of Infertility**

**Editors**  
**Vaclav Insler**  
**and**  
**Gerhard Bettendorf**

一九八四年九月十一日



---

# **ADVANCES IN DIAGNOSIS AND TREATMENT OF INFERTILITY**

Editors

**VACLAV INSLER and GERHARD BETTENDORF**

**KLAUS-H. GEISSLER, Associate Editor**

Symposium Held in Bad Reichenhall, West Germany  
June 30–July 3, 1980

Sponsored by **ORGANON**



**ELSEVIER/NORTH-HOLLAND**  
New York • Amsterdam • Oxford

---

ADVANCES IN DIAGNOSIS  
AND  
TREATMENT OF INFERTILITY

Elsevier North Holland, Inc.  
52 Vanderbilt Avenue, New York, New York 10017

Sole distributors outside USA and Canada:  
Elsevier Science Publishers B.V.  
P.O. Box 211, 1000 AE Amsterdam, The Netherlands

© 1981 by Elsevier North Holland, Inc.

Library of Congress Cataloging in Publication Data

Main entry under title:

Advances in diagnosis and treatment of infertility.

Bibliography: p.

Includes index.

1. Sterility—Congresses. I. Insler, Vaclav. II. Bettendorf, Gerhard. [DNLM: 1. Sterility—Diagnosis—Congresses. 2. Sterility—Therapy—Congresses. WP 570 A244 1980]

RC889.A38 616.6'92 80-28242

ISBN 0-444-00584-6

Editorial Services Barbara Conover

Design Edmée Froment

Design Editor Virginia Kudlak

Cover Design Paul Agule Design

Production Manager Joanne Jay

Compositor The Composing Room of Michigan, Inc.

Printer Haddon Craftsmen

Manufactured in the United States of America

---

## FOREWORD

---

The ORGANON symposia have become a tradition. They have always focused on reproductive medicine, and we were glad to have had the opportunity to participate in the organization of three of these events. The infertility symposium, however, differed from the previous ones because it had a broader scope. While the previous symposia dealt in depth with specific aspects of reproduction, the infertility symposium attempted to bring into focus the spectrum of human fertility problems. The papers presented and discussed, as well as the informal talks, stressed the necessity of a team approach.

Infertility is a complex process involving medical, psychological, and social aspects in women and men. The medical profession's obligation toward infertile couples will be fulfilled only when all these aspects are considered. This has to be accomplished by a joint effort of various specialists united in one medical discipline: reproductive medicine. It is our hope that this symposium will contribute to the realization of this goal.

We would like to express our appreciation to ORGANON and particularly to Dr. Günter Weiland for sponsoring and organizing this meeting. Thanks are also owed to all those who participated in and contributed to the scientific program. We are grateful to Mr. Yale Altman of Elsevier North Holland, Inc., New York, for his cooperation.

Vaclav Insler  
Gerhard Bettendorf



# CONTENTS

## Foreword

xi

## PART ONE OVULATION DISTURBANCES

1

### SECTION ONE GONADOTROPIN-RELEASING HORMONE AND GONADOTROPIN

3

#### GONADOTROPIN-RELEASING HORMONE AND ITS AGONISTS FOR INDUCTION OF FOLLICULAR MATURATION AND OVULATION

5

S. J. Nillius, G. Skarin, and L. Wide

#### TREATMENT OF INFERTILITY IN HYPOTHALAMIC AMENORRHEA WITH CHRONIC INTERMITTENT (PULSATILE) ADMINISTRATION OF Gn-RH USING A PORTABLE COMPUTERIZED PUMP

11

G. Leyendecker, T. Struve, L. Wildt, W. Nocke, and M. Hansmann

#### OVERALL RESULTS OF GONADOTROPIN THERAPY

21

G. Bettendorf, W. Braendle, Ch. Sprotte, Ch. Weise, and R. Zimmermann

#### THERAPY WITH GONADOTROPINS: WHERE ARE WE TODAY? ANALYSIS OF 2890 MENOTROPIN TREATMENT CYCLES IN 914 PATIENTS

27

B. Lunenfeld, D. M. Serr, S. Mashlach, G. Oelsner, J. Blankstein, J. Dor,  
Y. Frenkel, Z. Ben-Raphael, D. Tikotzky, and M. Snyder

#### EFFECT OF AN FSH PREPARATION WITH LOW LH ACTIVITY IN OVARIAN INSUFFICIENCY DISPLAYING HIGH LH/FSH RATIO

33

W. Braendle, S. Starcevic, and G. Bettendorf

#### EFFECT OF GONADOTROPIN TREATMENT DURING INHIBITED PITUITARY FUNCTION

43

G. Bettendorf, W. Braendle, C. Weise, and W. Poels

|  |     |
|--|-----|
| SEQUENTIAL STEROID/GONADOTROPIN THERAPY  | 53  |
| R. Kaiser  |     |
| PLASMA-17 $\beta$ -ESTRADIOL AND PLASMA PROGESTERONE AS INDICATORS OF CYCLIC CHANGES IN THE FOLLICLE-BEARING OVARY | 57  |
| S. Nitschke-Dabelstein, G. Sturm, H. Prinz, and R. Buchholz  |     |
| MODERATOR'S SUMMARY: SECTION ONE   | 65  |
| M. Breckwoldt  |     |
| SECTION TWO HYPERPROLACTINEMIA   | 67  |
| RESULTS OF TREATMENT OF ANOVULATION ASSOCIATED WITH HYPERPROLACTINEMIA   | 69  |
| M. Breckwoldt, F. Peters, and H. P. Zahradnik  |     |
| LONG-TERM FOLLOW-UP OF MEDICALLY TREATED HYPERPROLACTINEMIA INCLUDING PROLACTINOMA: EVIDENCE FOR CURE              | 79  |
| H. S. Jacobs and S. U. Thobani   |     |
| OVULATORY INFERTILITY AND THE ROLE OF BROMOCRIPTINE  | 85  |
| I. D. Cooke, E. A. Lenton, R. Sulaiman, and O. Sobowale  |     |
| TREATMENT OF OVARIAN INSUFFICIENCY ASSOCIATED WITH DYSPROLACTINEMIA  | 95  |
| W. Braendle, M. Carstensen, and G. Bettendorf  |     |
| MODERATOR'S SUMMARY: SECTION TWO   | 101 |
| S. J. Nillius and H. S. Jacobs   |     |
| SECTION THREE STEROIDS AND STEROID-LIKE OVULATION-INDUCING AGENTS  | 103 |
| THE ENDOCRINE SHIFT FROM A NORMAL CYCLE TO ANOVULATION   | 105 |
| F. Lehmann and G. Bettendorf   |     |
| TREATMENT OF FUNCTIONAL INFERTILITY WITH CLOMIPHENE CITRATE  | 115 |
| H.-D. Taubert, H. Kuhl, P. Haiges, and R. Baumann  |     |
| RECENT EXPERIENCE WITH AN INDIVIDUALIZED CLOMIPHENE TREATMENT REGIMEN INCLUDING ITS EFFECT ON THE POSTCOITAL TEST  | 123 |
| C. M. March, M. Gysler, E. J. Bailey, and D. R. Mishell  |     |
| ROLE OF EPIMESTROL IN INDUCTION OF OVULATION WITH SPECIAL REFERENCE TO 126 PREGNANCIES                             | 131 |
| J. Hammerstein and B. Schmidt  |     |
| MODERATOR'S SUMMARY: SECTION THREE   | 137 |
| V. Insler  |     |

**PART TWO SPECIAL ASPECTS OF INFERTILITY 139****MASTODYNIA: A CLINICAL SYMPTOM OF HYPERPROLACTINEMIA? 141**

F. Peters and M. Breckwoldt

**STRESS PROFILES IN NORMAL INFERTILE COUPLES: PHARMACOLOGICAL AND PSYCHOLOGICAL APPROACHES TO THERAPY 143**

R. F. Harrison, A. M. O'Moore, R. R. O'Moore, and J. R. McSweeney

**DOCTOR-PATIENT RELATIONSHIP DURING TREATMENT OF INFERTILITY 159**

V. Frick-Bruder, W. Braendle, and G. Bettendorf

**SOME EPIDEMIOLOGICAL ASPECTS OF FERTILITY EVALUATION 165**

V. Insler, G. Potashnik, and M. Glassner

**THE INFERTILE COUPLE: A QUANTITATIVE APPROACH TO THE EVALUATION OF EACH PARTNER 179**

E. Steinberger, L. J. Rodriguez-Rigau, and K. D. Smith

**MODERATOR'S SUMMARY: PART TWO 189**

I. D. Cooke

**PART THREE CERVICAL FACTOR 193****CERVICAL CRYPTS AND THEIR ROLE IN STORING SPERMATOZOA 195**

V. Insler, M. Glezerman, D. Bernstein, L. Zeidel, and N. Misgav

**IMMUNE REACTIONS IN HUMAN CERVICAL MUCUS AND SERUM AGAINST A SPERMATOZOAL "HAPTAN" 213**

L. Mettler

**SIGNIFICANCE OF PROGRESSIVELY MOTILE SPERMATOZOA IN THE POSTCOITAL TEST FOR THE FERTILITY PROGNOSIS 229**

J. Kremer

**IMMUNOLOGIC INFERTILITY: PREGNANCIES IN PATIENTS WITH SPERM ANTIBODY ACTIVITY 235**

K. S. Moghissi, A. G. Sacco, and K. Borin

**IN VITRO TREATMENT OF DISTURBED SPERM-MUCUS INTERACTION 243**

K. H. Broer

**MODERATOR'S SUMMARY: PART THREE 253**

M. Elstein

|   |            |
|---|------------|
| <b>PART FOUR MECHANICAL DISTURBANCES</b>  | <b>257</b> |
| LAPAROSCOPY IN THE DIAGNOSIS OF MECHANICAL INFERTILITY  | 259        |
| J. M. Phillips  |            |
| HYSTEROSCOPY AS AN AID IN THE DIAGNOSIS OF INFERTILITY  | 263        |
| H.-J. Lindemann   |            |
| THREE-STEP THERAPY FOR ENDOMETRIOSIS IN INFERTILITY   | 271        |
| K. Semm   |            |
| IMPACT OF MICROSURGERY IN GYNECOLOGY  | 277        |
| V. Gomel  |            |
| MICROSURGERY FOR MALE INFERTILITY   | 285        |
| P. Devroey and R. Schoysman   |            |
| MODERATOR'S SUMMARY: PART FOUR  | 291        |
| V. Gomel  |            |
| <b>PART FIVE MALE INFERTILITY</b>   | <b>293</b> |
| TRIAL OF AN LH-RH AGONIST FOR THE TREATMENT OF MALE INFERTILITY                                 | 295        |
| E. Nieschlag and M. von der Ohe   |            |
| ENDOCRINE AND SEMEN CHANGES AFTER SURGERY FOR VARICOCELE  | 301        |
| J. Frick, C. Danner, and G. Kunit   |            |
| ENDOCRINE AND MORPHOLOGIC OBSERVATIONS IN THE SERTOLI-CELL-ONLY SYNDROME AND RELATED CONDITIONS | 307        |
| B. Fredricsson, C. Björk, K. Carlström, and L. Plöen  |            |
| RECOVERY OF HUMAN TESTICULAR FUNCTION SUPPRESSION CAUSED BY DIBROMOCHLOROPROPANE                | 313        |
| G. Potashnik, I. Yanai-Inbar, and I. Sober  |            |
| ACROSIN AND SEMINAL PLASMA PROTEINASE INHIBITORS IN THE DIAGNOSTIC WORKUP OF MALE INFERTILITY   | 321        |
| W.-B Schill   |            |
| EFFECTS OF KALLIKREIN ON MALE SUBFERTILITY—A DOUBLE-BLIND CROSS-OVER STUDY                      | 339        |
| N. A. Bedford and M. Elstein  |            |
| SOME FACTORS AFFECTING SUCCESS OF ARTIFICIAL DONOR INSEMINATION: SURVEY OF 253 COUPLES          | 345        |
| M. Glezerman, and V. Insler   |            |



A COMPARATIVE MORPHOLOGICAL ANALYSIS OF ABNORMAL  
HUMAN SPERMATOZOA 355

B. Bartoov, J. Fisher, F. Eltes, J. Langsam, and B. Lunenfeld

FLOW-CYTOMETRY OF HUMAN SPERMATOZOA BEFORE AND  
AFTER PENETRATION OF CERVICAL MUCUS 375

G. Freundl, N. Hofmann, F. J. Otto, and H. Hettwer

MODERATOR'S SUMMARY: PART FIVE 385

E. Steinberger

---

**PART SIX CONCLUSIONS** 391

---

MODERATOR'S SUMMARY OF GENERAL DISCUSSION ON  
ANOVULATORY INFERTILITY 393

G. Bettendorf

MODERATOR'S SUMMARY OF GENERAL DISCUSSION ON MALE  
INFERTILITY 397

B. Lunenfeld

CLOSING REMARKS 399

V. Insler

**Index** 401

PART ONE

---

## OVULATION DISTURBANCES

---

OVULATION DISTURBANCES

SECTION ONE

---

**GONADOTROPIN-RELEASING  
HORMONE AND GONADOTROPIN**

---



SECTION ONE

---

HORMONE AND GONADOTROPIN  
GONADOTROPIN-RELEASING

---

# GONADOTROPIN-RELEASING HORMONE AND ITS AGONISTS FOR INDUCTION OF FOLLICULAR MATURATION AND OVULATION

---

S. J. NILLIUS, G. SKARIN, AND L. WIDE

---

The hypothalamic gonadotropin-releasing hormone was isolated, structurally determined, and synthesized by Schally and his co-workers in 1971. Luteinizing hormone-releasing hormone (LRH) was found to stimulate the pituitary synthesis and release of not only luteinizing hormone (LH) but also follicle-stimulating hormone (FSH) (Schally et al., 1971). Initial studies with natural and synthetic LRH suggested that the hormone should find practical clinical applications (Schally et al., 1971, 1972). It was hoped that LRH would prove particularly useful for diagnosis and treatment of infertility.

Because synthetic LHR preparations became available the potential diagnostic and therapeutic use of gonadotropin releasing hormone has been explored extensively. To enhance and simplify treatment, superactive analogs of LRH with prolonged biological activity have been synthesized (Schally et al., 1976). It is generally agreed that LRH is of limited value in diagnostic evaluation of female infertility. Single determinations of FSH and prolactin in serum and the exogenous progesterone are the only distinguishable investigative tools for selection of anovulatory women for treatment with ovulation-inducing agents (Bergh et al., 1978). Clinical trials with LRH were performed over several years before an effective therapeutic regimen was established. Chronic intermittent treatment (subcutaneous injections of 500  $\mu$ g of LRH every 8 hours) proved to be effective in inducing potency and spermatogenesis in hypogonadal men (Mortimer et al., 1974) and follicular maturation and ovulation in women with amenorrhea (Nillius et al., 1975).

In the female, the most relevant indication for LRH therapy is induction of follicular maturation and ovulation in those amenorrheic women who at present have to be treated with human gonadotropins. LRH might also be used for timing of ovulation in normally menstruating women in association with artificial insemination, and for induction of ovulation in anovulatory women, in whom follicular maturation has been elicited by clomiphene citrate or human


Supported by grant 13x - 3145 from the Swedish Medical Research Council.

menopausal gonadotropins (hMG). For discussions of these indications the reader is referred to previous reviews on the therapeutic use of LRH in the human female (Nillius 1976, 1979; Nillius et al., 1978). This chapter reviews the therapeutic use of LRH and one of its new potent agonists in amenorrheic infertile women.

### CHRONIC INTERMITTENT LRH TREATMENT

The therapeutic regimen with self-administration of LRH subcutaneously every 8 hours proved to be effective in clomiphene-resistant amenorrheic women with no signs of endogenous estrogen production (Mortimer et al., 1975; Nillius et al., 1975; Nillius and Wide, 1975; Henderson et al., 1976). By prolonged treatment with LRH only, it was possible to induce follicular growth and maturation, ovulation, and corpus luteum formation in amenorrheic women who had been practically devoid of ovarian activity before the treatment. Figure 1 shows an LRH treatment resulting in pregnancy in an estrogen-deficient woman who had experienced amenorrhea for 9 years. She had previously had a child after treatment with human gonadotropins and monitoring by daily estrogen determinations. During the LRH treatment she self-administered the

**FIGURE 1.** Chronic intermittent treatment with 500  $\mu$ g of LRH subcutaneously every 8 hours in a woman with long-standing amenorrhea. Basal body temperature and serum levels of estradiol and progesterone during a treatment resulting in pregnancy. Reproduced from Nillius, 1979.



hormone at home and after 30 days of treatment returned pregnant without any symptoms or signs of ovarian hyperstimulation.

Chronic intermittent administration of a constant dose of the single gonadotropin-releasing hormone had not only normalized basal FSH and LH secretion but also induced a cyclic gonadotropin pattern with differential changes of LH and FSH responses to LRH during the treatment (Nillius and Wide, 1979). The maximal FSH levels were obtained during the first days of treatment. However, the FSH levels rapidly decreased during the treatment and this decrease became more marked when the estrogen secretion from the ovaries started to rise. The LH responses, on the other hand, progressively increased during the treatment and in most patients reached maximal midcycle peak levels concomitant with high estrogen levels consistent with full follicular maturation.

The striking changes in the gonadotropin responses to LRH during the prolonged treatment may give LRH therapy an advantage over hMG for induction of follicular growth and maturation. The feedback system between the ovaries and the pituitary is intact in patients treated with LRH. This internal control mechanism may automatically prevent excessive FSH stimulation of the ovaries during prolonged treatment with LRH. The FSH response to LRH decreases when the estrogen levels rise concomitant with follicular maturation.

Fourteen amenorrheic women with no signs of endogenous estrogen production were given chronic intermittent therapy with 500  $\mu$ g of LRH every 8 h for 28 days. Follicular maturation and ovulation were induced in 11 women. Two of the five women, who were treated for anovulatory infertility, became pregnant during the treatment course. However, low progesterone values during the premenstrual period suggested insufficient corpus luteum function in no less than 6 of 12 treatment cycles. In an attempt to improve luteal function, LRH was then given in combination with human chorionic gonadotropin.

Combined treatment with LRH and hCG was given during five treatment courses (Nillius and Wide, 1979). The treatment was monitored by daily estrogen determinations for optimal timing of hCG injection and one of the three infertile patients conceived. This patient was later delivered of a second child after combined LRH-hCG treatment.

Thus, in some anovulatory women it is possible to replace human gonadotropins by LRH. Amenorrheic patients with relatively high FSH responses to LRH seem to be particularly suitable for LRH therapy, but absence of pretreatment response to LRH does not preclude successful treatment with daily applications of LRH alone, although insufficient corpus luteum function often occurs. For effective treatment of anovulatory infertility, it is therefore necessary to combine LRH and hCG in order to secure normal ovulation and adequate corpus luteum function. This treatment has to be monitored by daily estrogen determinations. One of the big advantages of LRH therapy is then lost.

### CHRONIC LRH AGONIST TREATMENT

During the last few years stimulatory analogs of LRH have become available for clinical trials. One of the most potent LRH agonists is D-Ser (TBU)<sup>6</sup>-EA<sup>10</sup>-LRH (Sandow et al., 1978). The effect of this LRH analog on the gonadotropin and



gonadal steroids secretion was studied in 10 women with amenorrhea (Nillius and Wide, 1977). A comparison was made between the acute effects of a subcutaneous injection of 500  $\mu\text{g}$  of LRH and 10  $\mu\text{g}$  of LRH and 10  $\mu\text{g}$  of D-Ser (TBU)  $^6$ -EH  $^6$ -LRH. The FSH and LH release during the first 3 h was similar but the gonadotropin release during the remainder of the study period was greater after administration of the analog and so was the estradiol increase. Thus, the LRH agonist was shown to exhibit a more potent and prolonged effect on the gonadotropin secretion than did LRH.

Chronic treatment with daily subcutaneous injections of 10  $\mu\text{g}$  of LRH agonist was then instituted in seven amenorrheic women with no evidence of endogenous estrogen secretion (Skarin et al., 1980). The acute effect of the LRH agonist in these women is shown in Figure 2. There was an evident biphasic pattern of LH release with early and late peaks of LH combined with a gradual progressive FSH release. This pattern is similar to that described after extended pituitary stimulation by constant infusions of LRH. All women responded with

**FIGURE 2.** Acute effects of a potent LRH agonist on the serum LH, FSH, and estradiol levels in seven women with amenorrhea. Reproduced from Skarin et al., 1980.

